Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - EU Market Recap: FTSE 100 +0.53% to 7723.07, DAX +0.48% to 16617.29, CAC40 +0.52% to 7450.63, STOXX 600 +0.69% to 477.68

Jan 04 ,2024

  • Synopsis:

    • European equity markets closed higher. HealthCare, Utilities and Banks among the outperformers, while Technology, Retail and Travel/Leisure lag. Treasuries weaker with the curve bear steepening. Dollar extending gains vs yen but lagging vs euro and sterling. Gold up 0.5%. Bitcoin futures up 1.8%. WTI crude down 1.9%, off best levels. US equities mostly higher in Thursday midday trading.

    • Equity markets finding a modicum of support after turning defensive this week amid overbought conditions and stretched positioning and sentiment indicators. Movement coincided with backup in bond yields, as markets pared back aggressive rate cut expectations. FOMC minutes effectively endorsed market thinking on rate outlook. Focus in Europe on inflation data with German and French readings firmer up in line with expectations. Final composite and services PMIs see upward revision, but remains in recessionary territory. UK services sector activity at six-month high. BoE mortgage approval data supports expectations of a recovering housing market. Update from UK's BCC showed firms more confident about outlook in contrast to IoD update yesterday. UK PM Sunak tells ITV working assumption is general election to take place in H2 of 2024.

    • In corporate news flow, out of DACHs, GRENKE (GLJ.GR) reported Q4 new leasing business whilst - overnight - Evotec (EVT.GR) announced CEO transition and confirmed 2023 guidance; also, Newron (NWRN.SW) reported exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS). In the Benelux region, Sligro Food Group (SLIGR.NA) issued Q4 group revenue and Galapagos (GLPG.NA) announced a strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology; furthermore, ForFarmers (FFARM.NA) completed the acquisition of Piast Pasze. In France, TotalEnergies (TTE.FP) closed deals with Alimentation Couche-Tard for €3.4B and SPIE (SPIE.FP) acquired J.D. Euroconfort. In the UK, Next (NXT.LN) shares traded higher on the back of Q4 trading update but - in a different story - JD Sports Fashion (JD.LN) shares lsot as much as (25%) after cutting FY PBT guidance; Topps Tiles PLC (TPT.LN) also underperforming after group posted Q1 trading update with like-for-like sales down (7.1%) in Q1. Sky News reports, cites City sources, that Royal London is plotting £6B bid for bulk annuities arm of Lloyds Banking Group (LLOY.LN) subsidiary Scottish Widows.

  • Digest:

    • Sectors - STOXX Europe 600:

      • Outperformers:

        • Banks +1.81%, Utilities +1.63%, Health Care +1.36%, Financial Svcs +1.05%, Media +0.94%, Construct & Mtls +0.83%, Oil & Gas +0.70%, Ind Goods & Svcs +0.71%

      • Underperformers:

        • Retail (0.75%), Technology (0.38%), Travel & Leisure (0.30%), Chemicals (0.26%), Consumer Products and Services (0.20%), Real Estate +0.19%, Food, Beverage and Tobacco +0.23%, Basic Resources +0.35%, Autos & Parts +0.13%, Personal Care Drug and Grocery Stores +0.40%, Insurance +0.63%

    • Macro:

      • UK:

        • Rishi Sunak working towards general election in 'H2 of the year' (ITV)

        • In election year, Labour's Starmer appeals to voters with message of hope (Reuters)

      • Germany:

        • German coalition dilutes 2024 subsidy cuts after farmer backlash (Reuters)

        • Emissions fall by a fifth amid stagnant industrial output (FT)

        • Inflation rises to 3.8% in blow to rate-cut hopes (FT)

    • Peripheral markets:

      • Ireland:

        • Government could pay for medics to study in NI (BBC)

      • Italy:

        • Italy to put Africa development, AI at heart of its G7 presidency (Reuters)

        • Rome seeks to boost sale of electric cars 'made in Italy' (FT)

      • Spain:

        • Irregular migrant arrivals almost doubled in Spain in 2023 (Reuters)

      • Hungary

        • Hungary's debt servicing costs surge past Italy's to lead EU (Bloomberg)

      • Greece

        • Blinken may meet Mitsotakis in Hania, spokesman says (Kathimerini)

    • Company news:

      • Notable Gainers

        • +135.8% AGL.LN (ANGLE £0.31, +0.18) -- expects new DNA sample-to-answer molecular solution combining CTC and ctDNA analysis to be driver of product and pharma services sales

        • +34.4% NWRN.SW (Newron Pharmaceuticals CHF6.14, +1.57) -- reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)

        • +20.9% KURN.SW (Kuros Biosciences CHF4.69, +0.81) -- trial advancement and two 510(k) clearances from FDA related to its MagnetOs products

        • +17.1% TGP.LN (Tekmar Group £0.12, +0.02) -- contract

        • +12.5% LIKE.LN (Likewise Group £0.23, +0.03) -- trading update

        • +9.5% IPH.FP (Innate Pharma €2.78, +0.24) -- FDA lifts partial clinical hold placed on lacutamab IND

        • +7.3% TRIN.LN (Trinity Exploration & Production £0.44, +0.03) -- notes Trinidad & Tobago Finance Act 2023

        • +5.8% NXT.LN (Next £85.32, +4.68) -- trading update; share buybacks

        • +5.2% SECARE.SS (Swedencare SEK67.72, +3.38) -- Symrise (SY1.GR) purchased additional 8.3M shares in Swedencare at up to SEK 64/share

        • +3.1% NRC.NO (NRC Group NOK11.24, +0.34) -- contract

        • +2.9% ART.LN (Artisanal Spirits Company £0.53, +0.02) -- acquisition

        • +2.7% AZA.SS (Avanza Bank Holding SEK230.80, +6.00) -- Dec update

        • +2.4% ALO.FP (Alstom €11.28, +0.27) -- contract

        • +2.4% BAYN.GR (Bayer AG €35.27, +0.83) -- trial result

        • +2.2% BINV.SS (BioInvent International SEK17.80, +0.38) -- announces 2024 strategic priorities and anticipated milestones

        • +2.1% VICO.SS (Vicore Pharma Holding SEK14.60, +0.30) -- trial results

        • +1.9% IAG.LN (International Consolidated Airlines Group £1.53, +0.03) -- notes failure to come to agreement with unions calling for strike

        • +1.7% EQNR.NO (Equinor NOK334.95, +5.65) -- Sif Holding (SIFG.NA) confirms termination of Empire Wind 2 monopile contract

        • +1.5% NDX1.GR (Nordex €9.98, +0.15) -- order

        • +0.9% CA.FP (Carrefour €16.78, +0.15) -- selling Pepsi (PEP) products due to price dispute - Reuters

        • +0.6% MRK.GR (Merck KGaA €143.30, +0.85) -- expands colorectal cancer portfolio through licensing agreement with Inspirna; Inspirna to receive upfront payment of $45M

        • +0.2% LLOY.LN (Lloyds Banking Group £0.48, -0.00) -- Royal London plotting £6B bid for bulk annuities arm of Lloyds Banking Group subsidiary Scottish Widows - Sky News

      • Notable Decliners

        • -23.0% JD.LN (JD Sports Fashion £1.20, -0.36) -- trading update; lowers FY PBT ex-items guidance to £915-935M vs prior £1.04B

        • -18.3% EVT.GR (Evotec €17.43, -3.92) -- CEO transition; confirms 2023 guidance

        • -5.4% TPT.LN (Topps Tiles £0.47, -0.03) -- trading update

    • EU companies reporting tomorrow:

      • Trading Update: Sodexo (SW.FP), Volvo Car (VOLCAR.B.SS)

      • Traffic: Norwegian Air Shuttle (NAS.NO)

  • Data:

    • Economics:

      • Dec Services PMI

        • UK 53.4 vs prelim 52.7

        • Eurozone Dec Services PMI 48.8 vs prelim 48.1

        • Germany Dec Services PMI 49.3 vs cons 48.4 and prior 49.6

        • France Dec Services PMI 45.7 vs cons 44.3 and prior 45.4

        • Italy Dec Services PMI 49.8 vs cons 49.8 and prior 49.5

        • Spain Dec Services PMI 51.5 vs cons 51.2 and prior 51.0

        • Sweden Dec Services PMI 50.0 vs cons 49.8 and prior revised 48.5 from 48.3

      • Germany Dec Prelim CPI +3.7% y/y vs cons +3.7% and prior +3.2%; +0.1% m/m vs cons +0.1% and prior (0.4%)

        • EU Harmonised: +3.8% y/y vs cons +3.8% and prior +2.3%; +0.2% m/m vs cons +0.3% and prior (0.7%)

      • UK Dec

        • Mortgage Approvals 50.07K vs cons 48.5K and prior revised 47.89K from 47.38K

        • M4 Money Supply (0.1%) m/m vs cons +0.1% and prior +0.3%

      • France Dec Prelim CPI +3.7% y/y vs cons +3.8% and prior +3.5%; +0.1% m/m vs cons +0.2% and prior (0.2%)

        • EU Harmonised: +4.1% y/y vs cons +4.1% and prior +3.9%; +0.1% m/m vs cons +0.3% and prior (0.2%)

    • Markets:

      • WTI Crude (24-Feb): ($1.33) or (1.83%) to $71.37

      • €-$ +0.0037 or +0.34% to 1.0960

      • £-$ +0.0030 or +0.24% to 1.2696

      • €-£ +0.0011 to 0.8634

      • S&P 500 +0.44%

      • Performance year-to-date

        • FTSE 100: (0.13%)

        • DAX: (0.80%)

        • CAC: (1.23%)

        • MIB: +0.17%

        • Stoxx 600: (0.27%)

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE